|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 下肢浅静脉治疗术后的加压疗法:美国静脉论坛血管、外科学会、美国静脉学会、血管医学学会和国际静脉联盟的临床实践指南显示文摘一、指南的由来下肢浅静脉治疗术后应用压力治疗的方式是几代血管外科医师多年临床经验积累所得,现主要应用于大隐静脉剥脱术、下肢静脉点状剥脱术及静脉硬化治疗等。目前单就静脉硬化治疗而言,术后压力治疗的推荐也是基于相关文献及实验验证[1],但对于其他术式,尤其是对于大隐静脉的热消融术,目前还没有形成规范统一的建议,这也使得当前的压力治疗具有很大的临床差异性。 | Lurie F Lal BK Antignani PL Blebea J Bush R Caprini J Davies A Forrestal M Jacobowitz G Kalodiki E Killewich L Lohr J Ma H Mosti G Partsch H Rooke T Wakefield T 李丹(译) 陈程浩(译) 牛传强(译) 张靖(译) 黄建忠(译) | 2020 | 中华介入放射学电子杂志2020，8，4： | 16 |
| 2 | miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus显示文摘AIM: To investigate miR-200 family expression in Barrett's epithelium, gastric and duodenal epithelia, and esophageal adenocarcinoma. METHODS: Real-time reverse transcriptase-polymerase chain reaction was used to measure miR-200, ZEB1 and ZEB2 expression. Ingenuity Pathway Analysis of miR-200 targets was used to predict biological outcomes. RESULTS: Barrett's epithelium expressed lower levels of miR-141 and miR-200c than did gastric and duodenal epithelia (P < 0.001). In silico analysis indicated roles for the miR-200 family in molecular pathways that distinguish Barrett's epithelium from gastric and duodenalepithelia, and which control apoptosis and proliferation. All miR-200 members were downregulated in adenocarcinoma (P < 0.02), and miR-200c expression was also downregulated in non-invasive epithelium adjacent to adenocarcinoma (P < 0.02). The expression of all miR-200 members was lower in Barrett's epithelium derived high-grade dysplastic cell lines than in a cell line derived from benign Barrett's epithelium. We observed signif icant inverse correlations between miR-200 family expression and ZEB1 and ZEB2 expression in Barrett's epithelium and esophageal adenocarcinoma (P < 0.05). CONCLUSION: miR-200 expression might contribute to the anti-apoptotic and proliferative phenotype of Barrett's epithelium and regulate key neoplastic processes in this epithelium. | Cameron M Smith David I Watson Mary P Leong George C Mayne Michael Z Michael Bas PL Wijnhoven Damian J Hussey | 2011 | World Journal of Gastroenterology2011，17，8： | 13 |
| 3 | Clinical significance of lymphadenectomy in patients with gastric cancer显示文摘Approximately thirty percent of patients with gastric cancer undergo an avoidable lymph node dissection with a higher rate of postoperative complication. Comparing the D1 and D2 dissections,it was found that there is a significant difference in morbidity,favoured D1 dissection without any difference in overall survival. Subgroup analysis of patients with T3 tumor shows a survival difference favoring D2 lymphadenectomy,and there is a better gastric cancer-related death and non-statistically significant improvement of survival for node-positive disease in patients with D2 dissection. However,the extended lymphadenectomy could improve stage-specific survival owing to the stage migration phenomenon. The deployment of centralization and application of national guidelines could improve the surgical outcomes. The Japanese and European guidelines enclose the D2 lymphadenectomy as the gold standard in R0 resection. In the individualized,stageadapted gastric cancer surgery the Maruyama computer program(MCP) can estimate lymph node involvement preoperatively with high accuracy and in addition the Maruyama Index less than 5 has a better impact on survival,than D-level guided surgery. For these reasons,the preoperative application of MCP is recommended routinely,with an aim to perform 'low Maruyama Index surgery'. The sentinel lymph node biopsy(SNB) may decrease the number of redundant lymphadenectomy intraoperatively with a high detection rate(93.7%) and an accuracy of 92%. More accurate stage-adapted surgery could be performed using the MCP and SNB in parallel fashion in gastric cancer. | dezso tóth jános plósz miklós torok | 2016 | World Journal of Gastrointestinal Oncology2016，8，2： | 8 |
| 4 | Hematopoietic cell transplantation for Crohn’s disease;is it time?显示文摘AIM: To review all studies in the literature that have assessed Hematopoietic cell transplantation (HCT) and Crohn’s disease (CD) with the ultimate aims of determining if this is a viable treatment option for those with CD. A secondary aim was to review the above literature and determine if the studies shed further light on the mechanisms involved in the pathogenesis of CD. METHODS: An extensive Medline search was performed on all articles from 1970 to 2005 using the ; bone marrow transplant, stem cell, hematopoietic cell, Crohn’s disease and inflammatory bowel disease. RESULTS: We identified one case in which a patient developed CD following an allogeneic HCT from a sibling suffering with CD. Evidence for transfer of the genetic predisposition to develop CD was also identified with report of a patient that developed severe CD following an allogeneic HCT. Following HCT it was found that the donor (that had no signs or symptoms of CD) and the recipient had several haplotype mismatches in HLA class Ⅲ genes in the IBD3 locus including a polymorphism of NOD2/CARD15 that has been associated with CD. Thirty three published cases of patients with CD who underwent either autologous or allogeneic HCT were identified. At the time of publication 29 of these 33 patients were considered to be in remission. The median follow-up time was seven years, and twenty months for allogeneic and autologous HCT respectively.For patients who underwent HCT primarily for treatment of their CD there have been no mortalities related to transplant complications. CONCLUSION: Overall these preliminary data suggest that both allogeneic and autologous HCT may be effective in inducing remission in refractory CD. Thissupports the hypothesis that the hematolymphatic cells play a key role in CD and that resetting of the immune system may be a critical approach in the management or cure of CD. | Y Leung M Geddes J Storek R Panaccione PL Beck | 2006 | World Journal of Gastroenterology2006，12，41： | 5 |
| 5 | On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprineor 6-mercaptopurine intolerant IBD patients显示文摘AIM: To determine the tolerability and safety profile of a low-dose maintenance therapy with 6-TG in azathioprine (AZA) or 6-mercaptopurine (6-MP) intolerant inflammatory bowel disease (IBD) patients over a treatment period of at least 1 year.METHODS: Database analysis.RESULTS: Twenty out of ninety-five (21%) patients discontinued 6-TG (mean dose 24.6 mg; mean 6-TGN level 540 pmol/8×108 RBC) within 1 year. Reasons for discontinuation were GI complaints (31%), malaise (15%)and hepatotoxicity (15%). Hematological events occurred in three patients, one discontinued treatment. In the 6-TG-tolerant group, 9% (7/75) could be classified as hepatotoxicity. An abdominal ultrasound was performed in 54% of patients, one patient had splenomegaly.CONCLUSION: The majority of AZA or 6-MP-intolerant IBD patients (79%) is able to tolerate maintenance treatment with 6-TG (dosages between 0.3 and 0.4 mg/kg per d). 6-TG may still be considered as an escape maintenance immunosuppressant in this difficult to treat group of patients, taking into account potential toxicity and efficacy of other alternatives. The recently reported hepatotoxicity is worrisome and 6-TG should therefore be administered only in prospective trials. | Nanne KH de Boer Luc JJ Derijks Lennard PL Gilissen Daniel W Hommes Leopold GJB Engels Sybrand Y de Boer Gijsbertus den Hartog Piet M Hooymans Anja BU M(?)kelburg Barend D Westerveld Anton HJ Naber Chris JJ Mulder Dirk J de Jong | 2005 | World Journal of Gastroenterology2005，11，35： | 4 |
| 6 | Four cancer cases after esophageal atresia repair: Time to start screening the upper gastrointestinal tract显示文摘Esophageal atresia(EA) is one of the most common congenital digestive malformations and requires surgical correction early in life. Dedicated centers have reported survival rates up to 95%. The most frequent comorbidities after EA repair are dysphagia(72%) and gastroesophageal reflux(GER)(67%). Chronic GER after EA repair might lead to mucosal damage, esophageal stricturing, Barrett's esophagus and eventually esophageal adenocarcinoma. Several long-term follow-up studies found an increased risk of Barrett's esophagus and esophageal carcinoma in EA patients, both at a relatively young age. Given these findings, the recent ESPGHAN-NASPGHAN guideline recommends routine endoscopy in adults born with EA. We report a series of four EA patients who developed a carcinoma of the gastrointestinal tract: three esophageal carcinoma and one colorectal carcinoma in a colonic interposition. These cases emphasize the importance of lifelong screening of the upper gastrointestinal tract in EA patients. | Floor WT Vergouwe Madeleine Gottrand Bas PL Wijnhoven Hanneke IJsselstijn Guillaume Piessen Marco J Bruno René MH Wijnen Manon CW Spaander | 2018 | World Journal of Gastroenterology2018，24，9： | 3 |
| 7 | Analysis of nitrate,nitrite,andnitrate in biological fluids显示文摘 | Green LC Wagner DA Glogowski J Skipper PL Wishnok JS Tannenbaum SR | 1982 | Anal Biochem1982，126，1： | 2 |
| 8 | Lifetime physical activity and breast cancer risk in a multiethnic population:the Francisco Bay area breast cancer study显示文摘 | John EM Horn-ross PL Koo J | 2003 | Cancer Epidemiol Biomarkers Prev2003，12，111： | 2 |
| 9 | Hydrodynamic injection of viral DNA:a mouse model of acute hepatitis B virus infection显示文摘 | Yang PL Althage A Chung J | 2002 | Proc Natl Acad Sci USA2002，99，13： | 2 |
| 10 | Depression,introversion and mortality foIlowing stroke显示文摘 | Robinson RG Samurls J | 1993 | Aust N Z J Psychiatry1993，27，： | 1 |
| 11 | Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation显示文摘 | Adida C Crotty PL McGrath J etal | 1998 | AmJ Pathol1998，152，1： | 1 |
| 12 | Asenapine显示文摘 | Weber J McCormack PL | 2009 | CNS Drugs2009，23，9： | 1 |
| 13 | Dietary Intake and the Development of the Metabolic Syndrome: The Atherosclerosis Risk in Communi- ties Study 显示文摘 | Lutsey PL Steffen Stevens J | 2008 | Circulation2008，117，： | 1 |
| 14 | In vitro selection and evolution of functional proteins by using ribosome display显示文摘 | Hanes J Plückthun A | 1997 | Proc Natl Acad Sci USA1997，94，10： | 1 |
| 15 | Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation显示文摘 | Adida C Crotty PL McGrath J | 1998 | Am J Pathol1998，152，： | 1 |
| 16 | Diabetes insipidus and adipsic hypermatremia in a patient with a craniopharyngioma显示文摘 | Macias Batista A Martinez Martin F J de Pablos Velasco PL | 1999 | An Med Interna1999，16，2： | 1 |
| 17 | Bisphosphonates in the treatment of Charcot neuroarthropathy:a double-blind randomized controlled trial显示文摘 | Jude EB Selby PL Burgess J | 2001 | Diabetologia2001，44，11： | 1 |
| 18 | Sulindac metabolites induce caspase-and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells显示文摘 | Rice PL Kelloff J Sullivan H | 2003 | Mol Cancer Ther2003，2，9： | 1 |
| 19 | Hydrodynamic injection of viral DNA : a mouse model of acute hepatitis B virus infection 显示文摘 | Yang PL Ahhage A Chung J | 2002 | Proc Natl Acad Sci USA2002，99，13： | 1 |
| 20 | The role of ultrasound in renal insufficiency: the essentials显示文摘 | Khati N J Hill MC Kimmel PL | 2005 | Ultrasound Q2005，21，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员